Evidence map›Paper›PMID 41360739›Full record

ReviewEuropean heart journal. Cardiovascular Imaging2026

Evaluating natural history and treatment response in cardiac amyloidosis: the evolving role of multimodality imaging.

Amely Walser, Christoph Gräni, Simon F Stämpfli, Sarah A M Cuddy, Olivier F Clerc, Ardel J Romero Pabón, Shilpa Vijayakumar, Osnat Itzhaki Ben Zadok, Rodney H Falk, Sharmila Dorbala and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in European heart journal. Cardiovascular Imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Amely WalserCardiac Imaging, Department of Cardiology and Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, Zurich CH-8091, Switzerland.ORCID 0009-0000-0798-6034
Christoph GräniDepartment of Cardiology, Inselspital, University Hospital Bern, University of Bern, Bern, Switzerland.ORCID 0000-0001-6029-0597
Simon F StämpfliDepartment of Cardiology, Heart Centre Lucerne, Luzerner Kantonsspital, Lucerne, Switzerland.
Sarah A M CuddyAmyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Olivier F ClercAmyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Ardel J Romero PabónAmyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Shilpa VijayakumarAmyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Osnat Itzhaki Ben ZadokAmyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Rodney H FalkAmyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-3329-2033
Sharmila DorbalaAmyloidosis Program, Division of Cardiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.
Dominik C BenzCardiac Imaging, Department of Cardiology and Nuclear Medicine, University Hospital Zurich, Rämistrasse 100, Zurich CH-8091, Switzerland.ORCID 0000-0001-8627-726X

Funding

Noninvasive Cardiovascular Imaging Research Training ProgramT32HL094301 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI Marcelo F DI CARLI · 2010 to 2026
$7.8M
Elucidating Mechanisms of Cardiac Dysfunction Using Imaging and ProteomicsK99HL175107 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI CLERC, OLIVIER FLORIAN · 2024 to 2025
$214k
Amyloidosis FoundationAstraZenecaAttralus, and SiemensCAIM FoundationGAMBIT FoundationGE HealthcareImmanuel und Ilse Straub StiftungInnosuisseInternational Society of AmyloidosisNHLBI NIH HHS K99 HL175107NHLBI NIH HHS T32 HL094301NIH HHS T32 HL 094301NIH HHS T32 HL 094301.Novartis FoundationOlga Mayenfisch FoundationSwiss Heart FoundationSwiss National Science Foundation
6 · The paper itself

Abstract

Cardiac amyloidosis, characterized by the accumulation of misfolded proteins in the heart, is a major cause of restrictive cardiomyopathy. It includes two main forms-transthyretin and immunoglobulin light chain amyloidosis-and carries a poor prognosis if left untreated. With emerging new therapies, the growing need to assess treatment response highlights imaging biomarkers as valuable and promising surrogate endpoints. This review discusses current evidence on changes in imaging markers following treatment, contrasting them with the natural progression of the disease. The focus is on magnetic resonance and single photon emission tomography (SPECT) metrics, which have been found to detect treatment responses early, even before functional changes or clinical events occur, thus playing a key role in the management of cardiac amyloidosis. Once validated in larger studies with more data on reproducibility and linked to clinical outcomes, magnetic resonance and SPECT imaging markers could significantly improve disease monitoring and enable personalized care in cardiac amyloidosis. In an outlook to the future, the disruptive potential of amyloid binding positron emission tomography for evaluating amyloid load and treatment response is discussed.

Indexed as

AmyloidosisCardiomyopathiesMultimodal ImagingDisease ProgressionHumansMagnetic Resonance ImagingMagnetic Resonance Imaging, CinePrognosisTomography, Emission-Computed, Single-PhotonTreatment Outcomeamyloid PETATTR cardiomyopathycardiac amyloidosisCMRechocardiographySPECTtreatment response

Identifiers

PMID41360739
PMCPMC13376133

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.